STLN.US Starling Oncology, Inc.

Healthcare Medical Care Facilities USA Stocks
3.40 USD
Close of Nov 18, 2026
2.32 7.13
Market cap
USD 347M
P/E
-
P/B
0.76x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is STLN.US undervalued?

Graham number

The Graham number of Starling Oncology, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Starling Oncology, Inc. fundamental analysis

No fundamental analysis for Starling Oncology, Inc. yet.

Starling Oncology, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Starling Oncology, Inc.

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance a…

Full company profile